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Abstract
Background: Since 1990, reduction of tuberculosis (TB) mortality has been lower in South Africa than in other
high-burden countries in Africa. This research investigated the influence of routinely captured demographic and
clinical or programme variables on death in TB patients in the Free State Province.
Methods: A retrospective review of case information captured in the Electronic TB register (ETR.net) over the years
2003 to 2012 was conducted. Extracted data were subjected to descriptive and logistic regression analyses. The
outcome variable was defined as all registered TB cases with ‘died’ as the recorded outcome. The variables associated
with increased or decreased odds of dying in TB patients were established. The univariate and adjusted odds ratios
(OR and AOR) together with their corresponding 95% confidence intervals (CI) were estimated, taking the clustering
effect of the districts into account.
Results: Of the 190,472 TB cases included in the analysis, 30,991 (16.3%) had ‘died’ as the recorded treatment outcome.
The proportion of TB patients that died increased from 15.1% in 2003 to 17.8% in 2009, before declining to 15.4% in
2012. The odds of dying was incrementally higher in the older age groups: 8–17 years (AOR: 2.0; CI: 1.5–2.7), 18–49
years (AOR: 5.8; CI: 4.0–8.4), 50–64 years (AOR: 7.7; CI: 4.6–12.7), and ≥65 years (AOR: 14.4; CI: 10.3–20.2). Other factors
associated with increased odds of mortality included: HIV co-infection (males – AOR: 2.4; CI: 2.1–2.8; females – AOR: 1.9;
CI: 1.7–2.1) or unknown HIV status (males – AOR: 2.8; CI: 2.5–3.1; females – AOR: 2.4; CI: 2.2–2.6), having a negative
(AOR: 1.4; CI: 1.3–1.6) or a missing (AOR: 2.1; CI: 1.4–3.2) pre-treatment sputum smear result, and being a retreatment
case (AOR: 1.3; CI: 1.2–1.4).
Conclusions: Although mortality in TB patients in the Free State has been falling since 2009, it remained high at more
than 15% in 2012. Appropriately targeted treatment and care for the identified high-risk groups could be considered.
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Background
Numbers of deaths and concomitant mortality rates rep-
resent traditional measures of the burden and impact of
diseases and the state of public health [1]. Tuberculosis
(TB) ranks among the ten principal causes of death and
disability worldwide [2]. South Africa has one of the
world’s most serious TB epidemics that in recent
decades has been driven by the human immunodefi-
ciency virus (HIV) epidemic [3]. In 2015, among the 22
countries with the highest burden of TB, the country had
the fourth highest estimated incidence of TB and the
highest number of HIV-infected TB cases and deaths [4].
While South Africa has made notable progress in
reducing TB prevalence and deaths and improving treat-
ment outcomes for new smear-positive TB cases [5],
overall reduction of TB mortality of only 6% over the
years 1990 to 2013 is substandard considering that over
the same period TB deaths declined by 45% globally and
40% in the African region [6]. The World Health
Organization’s (WHO) ‘End TB Strategy’ has set the tar-
get to reduce TB deaths by 95% by the year 2035. In
order to reach this target, the proportion of people with
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TB who die from the disease should decline from a pro-
jected 15% in 2015 to 6.5% by 2025 [7].
TB and HIV control efforts in South Africa are mainly
driven by the public health sector following a district-
based primary health care (PHC) approach and provision
of free treatment and care services. Located in the centre
of South Africa bordering on Lesotho, the Free State has
an estimated population of 2.8 million [8]. TB was the
leading underlying cause of death in the province in 2013
[9]. In 2012, of the nine provinces it reported the fifth
highest TB incidence at 709 cases per 100,000 population,
the second highest TB death rate at 142 cases per 100,000
population, and the third highest prevalence of antenatal
HIV infection at 32.1% [10].
Understanding the factors leading to death following
TB diagnosis is important for prognostic purposes, but
also for programme planning and appropriate targeting
of care to high-risk groups. The study set out to estab-
lish the influence of routinely captured demographic and
clinical or programme variables on mortality in TB
patients in the Free State over the years, 2003–2012.
Methods
Setting and design
A retrospective record review of individual case informa-
tion captured in the Electronic TB register (ETR.net)
was conducted. Based on the WHO and International
Union Against Tuberculosis and Lung Disease (IUTLD)
format of recording and reporting, the electronic format
of TB case information collection and collation is widely
recognised as a valuable tool to gather and analyse TB
and TB-HIV surveillance data in order to monitor and
evaluate programme performance. The ETR.net was
implemented in South Africa in 2003. In the Free State,
TB case information is processed as follows: firstly, at
the primary healthcare facility level, data are recorded
in a paper-based treatment register; secondly, at the
subdistrict level, captured on the ETR.net; and, finally,
at the provincial level, aggregated for the province as a
whole [11].
Population, data management and measurements
The study population was defined as all cases in the
provincial surveillance population, i.e. all cases regis-
tered in the ETR.net, over the years 2003 to 2012. Du-
plicate entries were deleted and patient names removed
before data were extracted from the database. The
outcome variable was defined as all patients with ‘died’ –
as compared to ‘successful treatment’ (‘cured’ or
‘completed’) – as the recorded outcome (Fig. 1). Cases
with ‘not evaluated’, ‘failed’, ‘defaulted/LTFU’, ‘moved/
transferred out’ as the recorded outcome were ex-
cluded from the analysis.
Although the outcome ‘loss to follow up’ (LTFU) has
been associated with TB mortality [12, 13], it could not
be included in the current study due to the high pa-
tient mobility and lack of unique patient identifiers
and inter-linked ETR.net databases across facilities and
provinces. This meant that TB programme staff could
not trace patients to determine if they had taken up
treatment at another facility in the same or another
district or province and ‘LTFU’ cases were probably re-
corded as ‘defaulted’. However, a separate analysis was
conducted where the default/LTFU cases were consid-
ered to have died. The estimated odds ratios were then
compared to those when the defaulters/LTFU cases
were excluded. There were no statistically significant
differences in the estimated odds ratios except in the
age group ≥65 years where the odds ratio significantly
decreased (Table 1). Yet only 145 of the 12,370 cases
with default/LTFU as the recorded outcome represented
this age group. Also, compared to the fluctuating rate of
cases recorded as died over the study period, the trend in
cases recorded as default/LTFU remained relatively stable
(Fig. 2). Thus, the exclusion of the default/LTFU cases
from the final analysis implied minimal bias. The study
also excluded drug-resistant cases as they are not recorded
in the basic ETR.net, but in a separate Electronic Drug-
Resistant Tuberculosis Register (EDRWeb.net).
Two demographic variables were included in the analysis:
1) age (≤7 or 8–17 or 18–49 or 50–64 or ≥65 years) and 2)
gender (male or female). Five clinical or programme
variables that were significantly related to the study
outcome in univariate analysis were included in the
multivariate models: 1) HIV status (negative or posi-
tive or unknown), 2) pre-treatment sputum smear re-
sult (positive or negative or no result), 3) treatment
category (new or retreatment), 4) disease classification
(pulmonary TB [PTB] or extrapulmonary [EPTB] or
both), and 5) treatment delay (≤14 days or >14 days
after notification).
Analysis
All data were analysed using STATA 12 [14]. Percentage
was used to describe the mortality trend over the study
period. Association between the independent variables
and treatment outcome was established using the
Pearson’s χ2 test. Logistic regression analysis was con-
ducted to ascertain factors associated with death in TB
patients taking into account the clustering effect of the
districts. The univariate and multivariate adjusted odds
ratios (OR and AOR) together with their corresponding
95% confidence intervals (CI) were estimated. The
assumed significance level was 0.05. During the develop-
ment of the adjusted model an assessment was carried
out to determine if gender was significantly involved in
interactions with any of the other independent variables.
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Table 1 Risk factors for death in TB patients















Gender Female (Ref) 13 834 (44.64) 1 1 1 - -
Male 17 157 (55.30) 1.0 (0.9–1.2) 0.8 (0.6–1.0) 0.8 (0.7–0.9) - -
Age (years) ≤7 (Ref) 943 (3.04) 1 1 1 1 1
8–17 472 (1.52) 1.4 (1.2–1.6) 1.9 (1.6–2.3) 2.0 (1.5–2.7) 2.0 (1.3–3.2) 2.0 (1.8–2.2)
18–49 23 266 (75.07) 4.1 (3.8–4.5) 4.0 (3.0–5.4) 5.8 (4.0–8.4) 6.4 (4.5–9.0) 5.3 (3.6–7.9)
50–64 5 094 (16.44) 5.2 (4.1–6.6) 4.4 (2.9–6.5) 7.7 (4.6–12.7) 9.0 (6.0–13.4) 6.8 (3.9–12.1)
≥65 1 216 (3.92) 8.4 (7.2–9.9) 7.5 (6.1–9.2) 14.4 (10.3–20.2) 13.8 (10.1–18.9) 14.4 (9.9–21.0)
HIV status Negative (Ref) 1 787 (5.77) 1 1 1 1 1
Positive 10 748 (34.68) 2.2 (2.0–2.5) 1.6 (1.4–1.9) 1.8 (1.6–2.1) 2.4 (2.1–2.8) 1.9 (1.7–2.1)
Unknown 18 456 (59.55) 2.8 (2.6–3.0) 1.9 (1.7–2.1) 2.4 (2.2–2.5) 2.8 (2.5–3.1) 2.4 (2.2–2.6)
Pre-treatment sputum
smear result
Smear + (Ref) 12 047 (38.87) 1 1 1 1 1
Smear - 7 375 (23.80) 1.5 (1.4–1.7) 1.3 (1.2–1.5) 1.4 (1.3–1.6) 1.4 (1.2–1.6) 1.5 (1.3–1.6)
No result 11 569 (37.33) 1.6 (1.4–1.8) 1.9 (1.4–2.6) 2.1 (1.4–3.2) 2.3 (1.5–3.4) 2.0 (1.3–3.1)
Treatment category New (Ref) 24 587 (79.34) 1 1 1 1 1
Retreatment 6 404 (20.66) 1.4 (1.3–1.5) 1.4 (1.3–1.5) 1.3 (1.2–1.4) 1.3 (1.2–1.4) 1.3 (1.2–1.4)
Disease classification Both (Ref) 776 (2.50) 1 1 1 1 1
PTB 23 210 (74.89) 1.3 (1.0–1.5) 1.0 (1.0–1.1) 1.0 (0.9–1.1) 1.0 (0.8–1.2) 1.0 (0.7–1.4)
EPTB 7 005 (22.60) 0.8 (0.6–0.9) 1.1 (0.9–1.3) 1.0 (0.8–1.2) 1.0 (0.8–1.1) 1.0 (0.7–1.3)
Treatment delay ≤14 days (Ref) 12 820 (41.37) 1 1 1 1 1
>14 days 3 244 (10.47) 1.0 (0.9–1.1) 0.9 (0.9–1.0) 0.9 (0.9–1.0) 0.9 (0.8–1.0) 0.9 (0.9–1.0)
Missing 14 927 (48.17) 1.4 (1.3–1.5) 1.1 (0.9–1.2) 1.0 (0.9–1.2) 1.0 (0.9–1.1) 1.1 (0.9–1.3)
HIV status x gendera Male x HIV
positive
- - 1.23 (1.15–1.32) 1.33 (1.26–1.41) - -
Male x HIV
unknown
- - 1.16 (1.09–1.25) 1.20 (1.15–1.25) - -
OR odds ratio; AOR adjusted odds ratio; CI confidence interval
aAdjusted for HIV status, gender and HIV status x gender interaction
Fig. 1 Overview of TB cases selected for the study
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There was a significant interaction between gender and
HIV status which was taken into consideration in pre-
senting results for the adjusted model (Table 1).
Ethical considerations
Ethical clearance was granted by the Ethics Committee
of the Faculty of Health Sciences, University of the Free
State (ECUFS 186/2014). Given that the case informa-
tion was aggregated and anonymised at the provincial




A total of 190,472 cases were included in the study with
16.3% recorded as ‘died’ (Fig. 1). Mortality among TB
patients increased from 15.1% in 2003 to 17.8% in 2009
before declining to 15.4% in 2012 (Fig. 2).
Table 1 depicts the demographic and clinical or
programme risk factors for death in TB patients.
Demographic variables
More than half (55.3%) of the patients who died were
males. Gender was not independently associated with
mortality (OR: 1.0; CI: 0.9–1.2), however, after adjusting
for other variables in the model, the risk of dying among
males was significantly lower compared to females
(AOR: 0.8; CI: 0.7–0.9). The large majority (n = 23,266;
75.1%) of TB patients that died were aged 18–49 years.
Advancing age was independently associated with death
in TB patients and the strength of this association in-
creased after adjusting for other variables in the model.
Compared to those in the 0–7 years age group, the odds
of death increased from 2.0 (CI: 1.5–2.7) in the 8–17
year old group to 14.4 (CI: 10.3–20.2) in the ≥65 year
old group. Table 1 shows that the odds of mortality was
higher for males compared to females in the age group
18–49 years – males (AOR: 6.4; CI: 4.5–9.0) and females
(AOR: 5.3; CI: 3.6–7.9) and in the age group 50–64
years – males (AOR: 9.0; CI: 6.0–13.4) and females
(AOR: 6.8; CI: 3.9–12.1). The odds of death was
higher for females (AOR: 14.4: CI 9.9–21.0) in the
age group >65 years than for males (AOR: 13.8: CI
10.1–18.9).
Clinical or programme variables
HIV co-infection (OR: 2.2; CI: 2.0–2.5) and unknown HIV
status (OR: 2.8; CI: 2.6–3.0) were independently associated
with increased likelihood of death while on TB treatment.
HIV status significantly interacted with gender and strati-
fied results indicate that the risk of death was higher
among both male (AOR: 2.4; CI: 2.1–2.8) and female
(AOR: 1.9; CI: 1.7–2.1) HIV-infected cases compared to
their respective HIV-uninfected counterparts. Likewise,
both male (AOR: 2.8; CI: 2.5–3.1) and female (AOR: 2.4;
CI: 2.2–2.6) TB cases with unknown HIV status had
higher risk of dying compared to their HIV-uninfected
counterparts. Having a negative (AOR: 1.4; CI: 1.3–1.6) or
a missing (AOR: 2.1; CI: 1.4–3.2) pre-treatment sputum
smear result was significantly associated with increased
risk for death in univariate analysis, with the risk increas-
ing after controlling for other factors included in the
model. Patients categorised as retreatment cases had
significantly higher risk of death in univariate analysis
(OR: 1.4; CI: 1.3–1.5) and only slightly lesser so in multi-
variate analysis (AOR: 1.3; CI: 1.2–1.4). Independently,
EPTB disease classification (OR: 0.8; CI: 0.6–0.9), as
compared to having both PTB and EPTB, was signifi-
cantly protective against death, but the association be-
came insignificant after adjusting for other factors in
the model.
Fig. 2 Death and default/LTFU in TB patients, 2003–2012
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Discussion
The record review in the Free State showed that mortality
in TB patients increased from 15.1% in 2003 to 17.8% in
2009, before declining to 15.4% in 2012, thus a net 10-year
increase of 0.3%. The steady rise in mortality in TB pa-
tients over the years 2003 to 2009 is variously attributed
to migration [15] and high levels of HIV co-infected
multidrug-resistant TB [16]. The marked decline in the
mortality trend after 2009 can possibly be attributed to
the progressive evolving of clinical eligibility requirements
for HIV co-infected TB cases to access antiretroviral treat-
ment (ART) [17], as well as heightened political attention
and international support and civil society mobilisation
around TB and HIV, including the launch of a national
HIV/TB campaign in 2011 [4, 18].
The record review in the Free State showed that TB
cases in older age groups had significantly increased odds
of death. Among the variables included in the unadjusted
and adjusted regression models, advancing age was the
strongest risk factor for mortality in TB patients. Com-
pared to cases aged 0–7 years, risk for death was
incrementally higher in each older age group. The greatest
proportion of deaths occurred among those aged 18–49
years. This corresponds to research in Limpopo [19] and
Western Cape [20] (South Africa) that associated higher
mortality in TB patients with advancing age. An inter-
national study observed that although TB age distributions
in Africa have been severely skewed by the HIV epidemic,
disease burdens among older people are increasing [21].
According to this study, older adults are more likely to
develop extrapulmonary and atypical forms of TB that are
often hard to diagnose. Older patients’ treatment and care
is also complicated by more frequent drug-related adverse
events and increased co-morbidity.
When adjusting for other factors, male gender was
significantly protective against death in TB patients in
the current study. This corresponds with the findings of
research in Western Cape that associated female gender
with increased risk of death in HIV-infected TB cases
[20]. The WHO reports that although globally the num-
bers of HIV-associated TB deaths were similar among
men and women in 2011, more deaths were estimated to
have occurred among women than men in the African
region, whilst in other regions more deaths were esti-
mated to have occurred in men [22]. The same source
states that TB in pregnant women living with HIV in-
creases the risk of maternal mortality by almost 300%
and that in Africa TB rates are about ten times higher
among pregnant women living with HIV than in their
HIV uninfected counterparts. A systematic review of
qualitative studies to identify gender-related barriers in
accessing TB diagnostic and treatment services showed
that women experience financial dependence, lower
general literacy and household stigma as barriers [23].
After advancing age, being co-infected with HIV or
having unknown HIV status was the strongest risk factor
for increased mortality in TB patients. However, for the
period under study, 2003 to 2012, the HIV status of the
majority (59.6%) of cases that died while on TB treat-
ment was unknown. Since integrated TB-HIV data gath-
ering in the ETR.net in the Free State started only in
2009, it was not possible to measure the effect of ART
and varying CD4 count levels on mortality in TB cases
for the whole study period. Recent research in Swaziland
revealed that high mortality in TB-HIV patients has per-
sisted despite increasing ART coverage in TB patients
[24]. A separate study is in process to measure the effect
of ART in TB-HIV co-infected cases in the Free State
for the years 2009 to 2012.
Not having a pre-treatment sputum smear result was
the third strongest risk factor for death in TB patients.
In KwaZulu-Natal (South Africa), research found that
over one-third of registered TB cases could not be con-
firmed based on laboratory results [25]. Many cases did
not have a laboratory record, lending to uncertainty
about the validity of the smear results and treatment
outcomes recorded in the ETR.net.
Having a negative pre-treatment sputum smear result
was the fourth strongest risk factor for death in TB
patients. Research in Malawi [26] and Zimbabwe [27]
established that smear-negative PTB patients presenting
with signs of concurrent HIV infection were at particu-
larly high risk of death. A systematic review has ex-
plained that in regions of high HIV prevalence poor
outcomes of smear-negative TB is a feature of advancing
immunosuppression and therefore higher risk of death
from other AIDS-related disease when compared to the
more robust immunological profile in patients with
smear-positive TB [28].
Being a retreatment case was the fifth strongest risk
factor for dying while on TB treatment. This is corrobo-
rated by similar research findings related to patients with
previous episodes of TB in Limpopo (South Africa) [19],
Uganda [29] and Malaysia [30]. In 2014, 6.7% of retreat-
ment as opposed to 1.8% of new cases in South Africa
had multidrug-resistant TB [4]. During most of the
study period, 2003–2012, culture was the main tool for
drug-susceptibility testing which implied a need for
trained personnel and expensive laboratory equipment
and long lengths of time to receive results while in the
interim patients were commonly commenced on drug-
sensitive TB regimens. The number of Xpert MTB/RIF
tests that were conducted in the province has since in-
creased from 1,199 in 2012 to 6,734 in 2013 and 8,062
in 2014 [31]. Expansion of the use of Xpert MTB/RIF is
expected to have a substantial overall TB mortality re-
duction effect in Africa if wide population coverage can
be achieved [32]. Further research may be necessary to
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understand its influence on the outcomes of retreatment
cases specifically. Xpert MTB/RIF is also an effective
method to diagnose smear-negative TB [33].
Most surveillance and notification systems are affected
by a degree of underestimation and therefore uncertainty
surrounds the 'true’ incidence of disease affecting mor-
bidity and mortality rates [34]. Electronic reviews are
also limited in the range of variables that can be in-
cluded for purposes of explaining risk for mortality
among TB patients. The register reflects only all-cause
mortality; it does not specify whether the death was
actually TB-related. Another limitation of study is that
since integrated TB-HIV data gathering in the ETR.net
in the Free State started only in 2009, it was not possible
to measure the protective effect of HIV-related clinical
interventions in TB-HIV co-infected patients for the
study period, 2003–2012.
Conclusions
Although the mortality among TB patients decreased
over the years 2009–2012, it remained high at more than
15%. The factors increasing the odds of death in TB
patients included advancing age, female gender, HIV co-
infection or unknown HIV status, having a negative or a
missing pre-treatment sputum smear result, and being a
retreatment patient. Appropriate targeting of care to
these high-risk groups could be considered.
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